MOST IMMEDIATE
CONFIDENTIAL

No.F.4-35/2016-DRAP/NHS,R&C
Government of Pakistan
Ministry of National Health Services, Regulations & Coordination,
LG & RD Complex, Sector G-5/2, Islamabad
****

"SAY NO TO CORRUPTION"

Islamabad, the 30th August, 2016.

Subject: **MINUTES OF THE MEETING OF THE COMMITTEE ON BLACK MARKETING OF 4 COMMONLY USED MEDICINES OF M/S GSK AND M/S ZAFA, THYROXINE TAB, MOTIVAL TAB, PANADOL CF TAB, AND FOLIC ACID TAB**

Please find enclosed herewith minutes of the meeting of Committee, constituted under the Chairmanship of Joint Secretary (Admn), Ministry of National Health Services, Regulations & Coordination (NHS,R&C) held on 26th August, 2016 to consider the progress on the subject matter, for further necessary action.

Enclosed: **As above.**

(Muhammad Saeed Awan)
Section Officer (Admn-I)
Ph # 051-9245792

i) Director (Costing & Pricing), DRAP.
ii) Director (MIS / H&OTC), DRAP.
iii) Director (Licensing & Quality Assurance), DRAP
iv) Secretary Registration Board, DRAP.
v) Mr. Khalid Mahmud, Representative of Transparency International of Pakistan.
vi) APS to JS (Admn), M/o NHS,R&C.

Letter 2018 file in Admn/DRAP folder

Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
LG & RD Complex, Sector G-5/2, Islamabad

Subject: **MINUTES OF THE MEETING OF THE COMMITTEE ON BLACK MARKETING OF 4 COMMONLY USED MEDICINES OF M/S GSK AND M/S ZAFA, THYROXINE TAB, MOTIVAL TAB, PANADOL CF TAB, AND FOLIC ACID TAB**

A meeting of the Committee on black marketing of 4 commonly used medicines, was held on 26th August, 2016 at 03:00 P.M in the office of the Joint Secretary (Admn), Ministry of National Heatlh Services, Regulations & Coordination (NHS,R&C) to consider progress and implementation by Drug Regulatory Authority of Pakistan (DRAP) on the earlier decisions of the Committee. The following attended the meeting:-

1.	Syed Moazzam Ali, JS (Admn), M/o NHS,R&C	Chairman
2.	Mr. Abdul Samad Khan, Director (Health & OTC), DRAP	Member
3.	Sheikh Faqeer Muhammad, Director (Licensing & Quality Assurance), DRAP	Member
4.	Dr. Obaidullah, Secretary Registration Board, DRAP	Member
5.	Mr. Khalid Mahmud, Representative of Transparency International-Pakistan	Member

Item No. 1

2. As per earlier decision of the Committee, Director (Costing & Pricing) has submitted detail report on MRP of Thyroxine Tablet, which was fixed by the Drug Pricing Committee (DPC) in its meeting held on 26-10-2011 and with the approval of Prime Minister. He has also produced minutes of the meeting of the DPC and a copy of letter dated 8th February, 2012, regarding circulation of minutes among the Pakistan Pharmaceutical Manufacturer Association and Pharma Bureau.

3. After perusal of the above mentioned record, Mr. Khalid Mahmood, Representative of Transparency International of Pakistan pointed out that Director (Costing & Pricing), DRAP has not clarified in its report that before establishment of DRAP, MRP used to be circulated among the members through minutes, instead of issuing notification. He also noted that as per the minutes of the Drug Pricing Committee, the price increase was given to Thyroxin which is the brand name of GSK and was not on generic basis. However, the Committee noted that many drug manufacturing companies use generic names for their brands and Thyroxin is also the brand and generic name used by GSK.

Decision: The Committee decided that Director (Costing & Pricing), DRAP should confirm in its report that before establishment of DRAP, MRP used to be circulated among the members through minutes instead of issuing notification. Revised report should be submitted within three (03) days.

Cont'd.....P/2...

From overleaf

Item No. 2

4. The Committee was informed by the Director (Licensing & Quality Assurance), DRAP that Chief Drugs Inspectors of all the provinces have already been asked to submit report on shortage of the following drugs, however, report is awaited:-

i) Thyroxine Tab.
ii) Motival Tab.
iii) Panadol CF Tab.
iv) Folic Acid Tab.
v) Dexamethason Tab.

5. He also informed that the data relating to import of raw material, production of registered products and sale record of these products for the year 2015-2016 is being submitted after obtaining from the field offices of DRAP.

Decision: The Committee considered the arguments of the Director (Licensing & Quality Assurance), DRAP and decided that:-

i) The letter issued to Chief Drugs Inspectors of provinces, should be endorsed to the representative of Transparency International of Pakistan for further necessary action if any.

ii) Further, it was also decided that DRAP should submit data / record relating to import of raw material, production of registered products and sale record of the above mentioned drugs for the last 05 years (2011 to 2015) within 07 days upto 1st September, 2016.